Objective: To compare volumes for epidural injection calculated on body weight or the length from sacrococcygeal space to occipital crest in dogs.

Study Design: Prospective study.

Animals: A total of 431 dogs weighing mean ± standard deviation (range) 24.6 ± 16.1 (1.3-88.0) kg and with vertebral column length 67.6 ± 38.4 (24.8-119.4) cm.

Methods: Dogs were separated into specific weight groups and body condition scores (BCS; 1-5): small (<10 kg), medium 10 to <25 kg), large (25 to <45 kg) and giant (≥45 kg). Calculations for a lumbosacral epidural dose were 0.2 mL kg and for vertebral column length: 0.05 mL cm (<50 cm), 0.07 mL cm (50 to <70 cm), 0.08 mL cm (70 to <80 cm), and 0.11 mL cm (≥80 cm). A split plot anova (p < 0.05) with weight, length and BCS as factors was used.

Results: A significantly larger volume was calculated for length than for weight in small (p < 0.0001-0.0003, BCS 2-5), medium (p < 0.0001-0.0076, BCS 2-5), and large dogs (p ≤ 0.0007-0.0019, BCS 2,3). In large (BCS 4,5) and giant dogs (BCS 2,3), both calculated volumes were similar. In giant dogs (BCS 4,5), a significantly smaller volume was calculated for length (p ≤ 0.0002-0.0165). Regardless of BCS, small (2.18 versus 1.12), medium (3.99 versus 3.16), and large dogs (7.38 versus 6.82) had larger calculated volumes (mL) for length than for weight (p < 0.0001), whereas giant dogs (10.04 versus 10.91) had smaller calculated volumes.

Conclusions: and clinical relevance Mathematically, the epidural volume of injectate varies with the calculation method and is affected by BCS. Small and medium dogs have larger calculated volumes based on length than on weight, and this difference tends to disappear or revert as size increases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaa.2018.10.002DOI Listing

Publication Analysis

Top Keywords

body weight
8
vertebral column
8
comparison calculated
4
calculated lumbosacral
4
lumbosacral epidural
4
epidural volumes
4
volumes injectate
4
injectate dose
4
dose regimen
4
regimen based
4

Similar Publications

The effects of the gut bacterial product, gassericin A, on obesity in mice.

Lipids Health Dis

January 2025

Department of Basic Sciences, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran.

Background: Obesity can arise from various physiological disorders. This research examined the impacts of the bacteriocin, gassericin A, which is generated by certain gut bacteria, using an in vivo model of obesity.

Methods: Fifty Swiss NIH mice were randomly assigned to five different groups.

View Article and Find Full Text PDF

Background: The prevalence of chronic kidney disease (CKD) is estimated to be about 13.4% worldwide. Studies have shown that CKD accounts for up to 2% of the health cost burden.

View Article and Find Full Text PDF

Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in participants with overweight or obesity, with or without diabetes: STEP 1 (n = 1,311) and STEP 2 (n = 645). We identified evidence supporting broad effects of semaglutide, implicating processes related to body weight regulation, glycemic control, lipid metabolism and inflammatory pathways.

View Article and Find Full Text PDF

Colon cancer is a significant health concern, and obesity is a well-established risk factor. However, previous studies have mainly focused on assessing body weight as a risk factor for colon cancer at a specific time point. This nationwide cohort study investigated the association between body weight changes, which can fluctuate throughout an individual's lifespan, and the incidence of colon cancer using the South Korean population database provided by the National Health Insurance Service (NHIS).

View Article and Find Full Text PDF

Introduction: Pediatric patients are more likely to experience medication-related errors and serious associated harms. The identification of high-risk medications (HRM) and their study in special populations, such as children with excess body weight (EBW), is a part of safety improvement strategies.

Objective: To generate, through a consensus technique structured by an interdisciplinary group of pediatricians and hospital pharmacists, an operational and updated list of HRM for hospital use in children over 2 years of age.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!